Motus GI Holdings Inc. priced its follow-on offering of 5 million common shares at $2.70 apiece.
The Fort Lauderdale, Fla.-based company also granted underwriters a 30-day option to buy an additional 750,000 common shares at the same price.
Motus GI expects gross proceeds of $13.5 million from the offering. The company plans to use net proceeds to fund commercialization and research and development activities, including the clinical and regulatory development of its product Pure-Vu.
The Pure-Vu System is cleared by the U.S. Food and Drug Administration to help clean a poorly prepared colon during colonoscopy.
Piper Jaffray & Co. is acting as the sole book-running manager for the offering, while A.G.P./Alliance Global Partners and Dougherty & Co. are acting as co-managers.